IO BIOTECH INC (IOBT)
US4497781090 - Common Stock
Taking everything into account, IOBT scores 2 out of 10 in our fundamental rating. IOBT was compared to 572 industry peers in the Biotechnology industry. While IOBT seems to be doing ok healthwise, there are quite some concerns on its profitability. IOBT is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year IOBT has reported negative net income.
In the past year IOBT has reported a negative cash flow from operations.
IOBT had negative earnings in each of the past 5 years.
IOBT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
IOBT has a Return On Assets of -100.44%. This is in the lower half of the industry: IOBT underperforms 76.46% of its industry peers.
IOBT's Return On Equity of -124.50% is in line compared to the rest of the industry. IOBT outperforms 40.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -100.44% | ||
| ROE | -124.5% | ||
| ROIC | N/A |
ROA(3y)-45.97%
ROA(5y)-105.42%
ROE(3y)-50.49%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for IOBT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for IOBT has been increased compared to 1 year ago.
There is no outstanding debt for IOBT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IOBT has an Altman-Z score of -5.82. This is a bad value and indicates that IOBT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.82, IOBT is doing worse than 65.49% of the companies in the same industry.
IOBT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.82 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
IOBT has a Current Ratio of 5.37. This indicates that IOBT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.37, IOBT is in line with its industry, outperforming 57.52% of the companies in the same industry.
IOBT has a Quick Ratio of 5.37. This indicates that IOBT is financially healthy and has no problem in meeting its short term obligations.
IOBT has a Quick ratio (5.37) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.37 | ||
| Quick Ratio | 5.37 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 44.31% over the past year.
EPS 1Y (TTM)44.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
IOBT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.31% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y35.87%
EPS Next 2Y17.05%
EPS Next 3Y13.02%
EPS Next 5Y13.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
IOBT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IOBT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IOBT's earnings are expected to grow with 13.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.05%
EPS Next 3Y13.02%
5. Dividend
5.1 Amount
No dividends for IOBT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IO BIOTECH INC
NASDAQ:IOBT (1/14/2025, 8:00:02 PM)
After market: 0.81 -0.02 (-2.29%)0.829
-0.03 (-3.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners76.66%
Inst Owner Change0%
Ins Owners0.24%
Ins Owner Change-0.04%
Market Cap54.61M
Analysts78.33
Price Target9.18 (1007.36%)
Short Float %0.07%
Short Ratio0.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.8%
Min EPS beat(2)-22.76%
Max EPS beat(2)13.17%
EPS beat(4)2
Avg EPS beat(4)1.91%
Min EPS beat(4)-22.76%
Max EPS beat(4)18.3%
EPS beat(8)4
Avg EPS beat(8)0.55%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.76%
PT rev (3m)9.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.48%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.75 | ||
| P/tB | 0.75 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.37
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-1.3
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0
BVpS1.1
TBVpS1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -100.44% | ||
| ROE | -124.5% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-45.97%
ROA(5y)-105.42%
ROE(3y)-50.49%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 59.84% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.37 | ||
| Quick Ratio | 5.37 | ||
| Altman-Z | -5.82 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.28%
EPS Next Y35.87%
EPS Next 2Y17.05%
EPS Next 3Y13.02%
EPS Next 5Y13.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.82%
EBIT Next 3Y-12.25%
EBIT Next 5YN/A
FCF growth 1Y-27.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.72%
OCF growth 3YN/A
OCF growth 5YN/A